Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
letter
. 2009 Jul 1;47(9):3058–3059. doi: 10.1128/JCM.00706-09

Prevalence of the Operon Encoding Subtilase Cytotoxin in Non-O157 Shiga Toxin-Producing Escherichia coli Isolated from Humans in the United States

Jennifer J Wolfson 1,*, Dakshina M Jandhyala 1, Lynn A Gorczyca 1, Zulekha Qadeer 1, Shannon D Manning 1, James Hadler 1, James T Rudrik 1, Cheleste M Thorpe 1
PMCID: PMC2738072  PMID: 19571032

Shiga toxin-producing Escherichia coli (STEC) causes diarrhea and can lead to hemolytic uremic syndrome (HUS). In addition to Shiga toxin (Stx), gene products encoded by the locus of enterocyte effacement (LEE) pathogenicity island are well-known virulence factors. This gene cluster is present in certain STEC strains that have caused large-scale outbreaks, such as O157:H7. STEC strains lacking LEE can also cause HUS, suggesting the importance of other virulence factors (4). A novel toxin called subtilase cytotoxin (SubAB) was discovered in a non-O157, LEE-negative Stx2-producing strain that caused a small HUS outbreak (9). The role of SubAB in HUS pathogenesis is unclear, but in a murine model, SubAB injected intraperitoneally causes widespread microangiopathic changes (similar to the pathology in humans with HUS) (10). Given that the gene for SubAB has not been detected in O157 STEC and non-O157 STEC sometimes lack a key STEC virulence factor (LEE), our objective was to estimate the prevalence of the subA gene among non-O157 STEC isolated from humans in the United States.

Other studies demonstrate the presence of subA in STEC from various sources in Brazil, Canada, and the United States (3, 5, 6). We previously identified subA in several non-O157 North American STEC strains, but the prevalence of subA in U.S. human STEC disease isolates is unknown (6). In Australia, approximately 10% of stool samples from humans with STEC disease contain subA (8).

A study conducted by the Michigan Department of Community Health examined stool samples by enzyme immunoassay for Stx's between April 2003 and October 2005 (7). Similarly, the Connecticut Department of Public Health reported on non-O157 STEC strains from Connecticut between 2000 and 2005 (1). We used multiplex PCR as previously described to genotype the non-O157 strains collected from these studies (6, 8). We identified the presence of subA and several other known virulence factors—eae, hly, stx1, and stx2.

Of the 153 non-O157 strains included for analysis, 21 lack LEE, and 3/21 are subA positive (Table 1). These three strains have virulence pattern profiles similar to those of most of the known subA-containing STEC strains (6, 8). They lack eae, the gene encoding intimin that is present in the LEE pathogenicity island, but contain hly (hemolysin) and stx2. One strain also has stx1.

TABLE 1.

subA-positive and eae-negative strains

Location No. (%) of:
subA-positive strains eae-negative strains subA-positive of eae-negative strains
Michigan 1/40 (2.5)a 7/40 (17.5) 1/7 (14.3)
Connecticut 2/113 (1.8)b 14/113 (12.4) 2/14 (14.3)
Total 3/153 (2) 21/153 (13.7) 3/21 (14.3)
a

Patient was an elderly female who presented to an outpatient facility. No clinical information is available. The strain was serotype O110:H28 and hly positive, eae negative, stx1 negative, and stx2 positive.

b

One of these two patients was a female in her twenties with bloody diarrhea and cramps, but no HUS. The strain was serotype O163:H19 and hly positive, eae negative, stx1 negative, and stx2 positive. The other patient was an asymptomatic teenager under evaluation for worms in stool. Strain was O91:H14 and hly positive, eae negative, stx1 positive, and stx2 positive.

Because of the low prevalence of strains with subA in this study, we are unable to form conclusions about SubAB's role in non-O157 STEC virulence. To assess the clinical significance of SubAB and gain understanding of its contribution to disease pathogenesis, large population-based epidemiologic studies should be performed where there is a higher prevalence of SubAB. Increased surveillance for both O157 and non-O157 STEC with enzyme immunoassay or PCR, as recommended by the Centers for Disease Control and Prevention, will allow future studies that can further characterize the burden of disease caused by non-O157 STEC and SubAB-producing STEC (2). Although subA-positive strains currently account for a small percentage of recognized STEC strains affecting humans in the United States, distribution of these strains could change over time. If LEE-positive STEC strains are successfully removed from the food chain, more LEE-negative strains may emerge. In the meantime, animal models and tissue culture studies may be helpful to expand our knowledge of the possible contribution of SubAB to STEC pathogenesis.

Footnotes

Published ahead of print on 1 July 2009.

REFERENCES

  • 1.CDC. 2007. Laboratory-confirmed non-O157 Shiga toxin-producing Escherichia coli—Connecticut, 2000-2005. MMWR Morb. Mortal. Wkly. Rep. 56:29-31. [PubMed] [Google Scholar]
  • 2.CDC. 2006. Importance of culture confirmation of Shiga toxin-producing Escherichia coli infection as illustrated by outbreaks of gastroenteritis—New York and North Carolina, 2005. MMWR Morb. Mortal. Wkly. Rep. 55:1042-1045. [PubMed] [Google Scholar]
  • 3.Cergole-Novella, M. C., L. S. Nishimura, L. F. Dos Santos, K. Irino, T. M. I. Vaz, A. M. M. Bergamini, and B. E. C. Guth. 2007. Distribution of virulence profiles related to new toxins and putative adhesins in Shiga toxin-producing Escherichia coli isolated from diverse sources in Brazil. FEMS Microbiol. Lett. 274329-334. [DOI] [PubMed] [Google Scholar]
  • 4.Johnson, K. E., C. M. Thorpe, and C. L. Sears. 2006. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin. Infect. Dis. 431587-1595. [DOI] [PubMed] [Google Scholar]
  • 5.Karama, M., R. P. Johnson, R. Holtslander, S. A. McEwen, and C. L. Gyles. 2008. Prevalence and characterization of verotoxin-producing Escherichia coli (VTEC) in cattle from an Ontario abattoir. Can. J. Vet. Res. 72297-302. [PMC free article] [PubMed] [Google Scholar]
  • 6.Khaitan, A., D. M. Jandhyala, C. M. Thorpe, J. M. Ritchie, and A. W. Paton. 2007. The operon encoding SubAB, a novel cytotoxin, is present in shiga toxin-producing Escherichia coli isolates from the United States. J. Clin. Microbiol. 451374-1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Manning, S. D., R. T. Madera, W. Schneider, and S. E. Dietrich, W. Khalife, W. Brown, T. S. Whittam, P. Somsel, and J. T. Rudrik. 2007. Surveillance for Shiga toxin-producing Escherichia coli, Michigan, 2001-2005. Emerg. Infect. Dis. 13:318-321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Paton, A. W., and J. C. Paton. 2005. Multiplex PCR for direct detection of Shiga toxigenic Escherichia coli strains producing the novel subtilase cytotoxin. J. Clin. Microbiol. 432944-2947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Paton, A. W., P. Srimanote, U. M. Talbot, H. Wang, and J. C. Paton. 2004. A new family of potent AB5 cytotoxins produced by Shiga toxigenic Escherichia coli. J. Exp. Med. 20035-46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wang, H., J. C. Paton, and A. W. Paton. 2007. Pathologic changes in mice induced by subtilase cytotoxin, a potent new Escherichia coli AB5 toxin that targets the endoplasmic reticulum. J. Infect. Dis. 1961093-1101. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES